163164-46-3

Basic information

• Product Name: 4 - (2 - ((Tetrahydro - 2H - pyran - 2 - yl)oxy)ethyl)benzaldehyde
• Synonyms: 4 - (2 - ((Tetrahydro - 2H - pyran - 2 - yl)oxy)ethyl)benzaldehyde;4-[2-(oxan-2-yloxy)ethyl]benzaldehyde（WS204754）
• CAS NO: 163164-46-3
• Molecular Formula: C₁₄H₁₈O₃
• Molecular Weight: 234.29092
• Mol File: 163164-46-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 368.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4 - (2 - ((Tetrahydro - 2H - pyran - 2 - yl)oxy)ethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4 - (2 - ((Tetrahydro - 2H - pyran - 2 - yl)oxy)ethyl)benzaldehyde(163164-46-3)
• EPA Substance Registry System: 4 - (2 - ((Tetrahydro - 2H - pyran - 2 - yl)oxy)ethyl)benzaldehyde(163164-46-3)

Safety Data

• Hazardous Substances Data: 163164-46-3(Hazardous Substances Data)

Usage

Uses

4-[2-[(Tetrahydro-2H-pyran-2-yl)oxy]ethyl]benzaldehyde is an intermediate in the synthesis of 4-(2-Hydroxyethyl)benzaldehyde (H827400), used in the synthesis of thromboxane receptor antagonists and -thromboxane synthase inhibitors based on a dioxane linkage.

Upstream product

• 79849-46-0 4-(2-(tetrahydropyran-2-yloxy)ethyl)bromobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 142-68-7 TETRAHYDROPYRANE 
• 163164-47-4 4-mono(2-hydroxyethyl)benzaldehyde 
• 4654-39-1 4-bromophenethanol 
• 110-87-2 3,4-dihydro-2H-pyran 

Downstream Products

• 1378963-37-1 4-(9-chloro-5,6-dihydro-4H-pyrrolo[1,2-a][1,4]benzodiazepin-4-yl)benzeneethanol 
• 1378963-35-9 4-(7,9-dichloro-5,6-dihydro-4H-pyrrolo[1,2-a][1,4]benzodiazepin-4-yl)benzeneethanol hydrochloride 
• 1251473-71-8 tert-butyl 6-(4-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)benzyIamino)hexylcarbamate 
• 1228117-25-6 (Z,Z)-5-[4-(2-hydroxyethyl)benzylidene]-2-isopropylimino-3-phenyl-thiazolidin-4-one 
• 1026872-84-3 (E)-7-{4-[2-(4-[1,3]Dioxan-2-yl-phenyl)-ethoxy]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid ethyl ester 
• 1026073-46-0 (E)-7-{4-[2-(4-Formyl-phenyl)-ethoxy]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid ethyl ester 
• 163164-07-6 4-(1,3-dioxan-2-yl)phenylethanol 
• 163164-47-4 4-mono(2-hydroxyethyl)benzaldehyde 

Relevant articles and documents

Method for compounding ether by dehydrogenation cross coupling reaction of iron catalyst alcohol and ether

The invention discloses a method for compounding ether by dehydrogenation cross coupling reaction of iron catalyst alcohol and ether, and belongs to the technical field of catalyzed synthesis. The reaction general formula is as shown in the specification. The method applies low-price and toxic-free iron as catalyst and silicon reagent as promoter, the ether compound by dehydrogenation cross coupling reaction of iron catalyst alcohol and ether is completed under the effect of oxidizing agent. The method applies the environmental-friendly iron catalyst, safe and pollution-free silicon reagent as the promoter so as to perform dehydrogenation cross coupling reaction of alcohol and ether; therefore, the method has good functional group compatibility and wide substrate application scale.

FLUOROPHORE AND FLUORESCENT SENSOR COMPOUND CONTAINING SAME

The invention provides fluorophores of formulae (I) and (II) and also fluorescent sensor compounds comprising fluorophore moieties based on such fluorophores in combination with a receptor moiety. There is further provided a method of sensing the presence of a target analyte using the fluorescent sensor compound, as well as the use of the fluorescent sensor compounds to sense a target analyte.

A Novel Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibitors Based on the Link of 1,3-Dioxane-Thromboxane Receptor Antagonists and -Thromboxane Synthase Inhibitors

A new class of dual-acting racemic thromboxane receptor antagonist/thromboxane synthase inhibitors is reported, based on the novel approach of linking the known thromboxane synthase inhibitors (TXSI) dazoxiben (2) or isbogrel (11) (separately) to thromboxane receptor antagonists (TXRA) from the 1,3-dioxane series, such as ICI 192605 (10).Dual activity was observed in vitro with inhibition of human microsomal thromboxane synthase in the range IC50 = 0.01-1.0 μM and receptor antagonist activity by inhibition of U46619-induced human platelet aggregation in the range pA2 = 5.5-7.0.The in vitro results also showed that very large groups could be tolerated at the selected substitution positions of the TXRA and TXSI components.Oral activity was observed in ex vivo tests in both rats and dogs at a dose of 10 mg/kg.Thus, (E)-7--4-(2-hydroxyphenyl)-1,3-dioxan-2-yl>benzyl>oxy>phenyl>-7-(3-pyridyl)hept-6-enoic acid (110) was both an antagonist (pA2 = 6.7) and a synthase inhibitor (IC50 = 0.02 μM)).On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity 64 (rat, 3 h) and >59 +/- 11.3 (dog, 2 h) vs ex vivo U46619-induced platelet aggregation>.Inhibition of thromboxane synthase at the respective time points in these experiments was 81 +/- 4.4percent (rat) and 69 +/- 4.8percent (dog).